Browsing by Author de Zeeuw, Dick

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 16 of 16
Issue DateTitleAuthor(s)Citation
2017Canagliflozin and cardiovascular and renal events in type 2 diabetesFulcher, Greg; Neal, Bruce; Perkovic, Vlado; de Zeeuw, Dick; Desai, Mehul; Erondu, N; Law, Gordon; Mahaffey, Kenneth W; Matthews, David; Shaw, Wayne; Northern Clinical School: Medicine; The George Institute for Global Health; The George Institute for Global HealthCanagliflozin and cardiovascular and renal events in type 2 diabetes, New England Journal of Medicine, vol.377, 7, 2017,pp 644-657
2018Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)Neal, Bruce; Perkovic, Vlado; Barrett, Terrance D; de Zeeuw, Dick; Desai, Mehul; Figtree, Gemma; Fulcher, Greg; Mahaffey, Kenneth W; Matthews, David. R.; Radholm, Karin; Shaw, Wayne; Solomon, Scott; The George Institute for Global HealthCanagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study), Circulation, vol.138, 5, 2018,pp 458-468
2018Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)Neal, Bruce; Perkovic, Vlado; Barrett, Terrance D; de Zeeuw, Dick; Desai, Mehul; Figtree, Gemma; Fulcher, Greg; Mahaffey, Kenneth W; Matthews, David. R.; Radholm, Karin; Shaw, Wayne; Solomon, Scott; The George Institute for Global HealthCanagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study), Circulation, vol.138, 5, 2018,pp 458-468
2018Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)Neal, Bruce; Perkovic, Vlado; Barrett, Terrance D; de Zeeuw, Dick; Desai, Mehul; Figtree, Gemma; Fulcher, Greg; Mahaffey, Kenneth W; Matthews, David. R.; Radholm, Karin; Shaw, Wayne; Solomon, Scott; The George Institute for Global HealthCanagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study), Circulation, vol.138, 5, 2018,pp 458-468
2009Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trialsCass, Alan; Gallagher, Martin; Grobbee, Diederick; Jardine, Meg; Lambers Heerspink, Hiddo; Neal, Bruce; Ninomiya, Toshiharu; Perkovic, Vlado; Zoungas, Sophia; de Zeeuw, Dick; Roberts, Matthew A.; School of Public Health: Medicine; Concord Clinical School: Medicine; The George Institute for Global Health; The George Institute for Global Health; The George Institute for Global Health; The George Institute for Global Health; The George Institute for Global Health; The George Institute for Global Health; The George Institute for Global HealthEffect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials, The Lancet, vol.373, 9668, 2009,pp 1009-1015
2014Effects of lowering LDL cholesterol on progression of kidney diseaseCraig, Jonathan; Agodoa, Lawrence; Baigent, C; Cass, Alan; de Zeeuw, Dick; Emberson, Jonathan; Feldt-Rasmussen, Bo; Fellstrom, Bengt; Haynes, Richard; Herrington, William; Landray, Martin J.; Levin, Adeera; Lewis, David; Reith, Christiana; Walker, Robert; Wheeler, David; School of Public Health: Public HealthEffects of lowering LDL cholesterol on progression of kidney disease, Journal of the American Society of Nephrology, vol.25, 8, 2014,pp 1825-1833
2014Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathyPerkovic, Vlado; Bakris, George; Davies, Melanie; de Zeeuw, Dick; Kline, Irina; Mayer, Cristiana; Meininger, G; Usiskin, K; Vijapurkar, Ujjwala; Woo, Vincent; Yamout, Hala; The George Institute for Global HealthEfficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy, American Journal of Nephrology, vol.40, 1, 2014,pp 64-74
2015Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled TrialFulcher, Greg; Neal, Bruce; Perkovic, Vlado; Capuano, George; de Zeeuw, Dick; Desai, Mehul; Mahaffey, Kenneth W; Matthews, David. R.; Meininger, G; Rosenstock, Julio; Shaw, Wayne; Vercruysse, Frank; Weiss, Robert; Northern Clinical School: Medicine; The George Institute for Global Health; The George Institute for Global HealthEfficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial, Diabetes Therapy, vol.6, 3, 2015,pp 289-302
2016Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetesFulcher, Greg; Neal, Bruce; Perkovic, Vlado; Capuano, George; de Zeeuw, Dick; Desai, Mehul; Mahaffey, Kenneth W; Mathieu, Chantal; Matthews, David. R.; Meininger, G; Shaw, Wayne; Vercruysse, Frank; Woo, Vincent; Wysham, C; Northern Clinical School: Medicine; The George Institute for Global Health; The George Institute for Global HealthEfficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes, Diabetes, Obesity and Metabolism, vol.18, 1, 2016,pp 82-91
2015Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 DiabetesFulcher, Greg; Neal, Bruce; Perkovic, Vlado; Alba, Maria; Capuano, George; de Zeeuw, Dick; Desai, Mehul; Jiang, Joel; Mahaffey, Kenneth W; Matthews, David; Meininger, G; Shaw, Wayne; Vercruysse, Frank; Ways, Kirk; Northern Clinical School: Medicine; The George Institute for Global Health; The George Institute for Global HealthEfficacy and Safety of Canagliflozin, an Inhibitor of Sodium Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes, Diabetes Care, vol.38, 3, 2015,pp 403-411
2014The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathyPerkovic, Vlado; Andress, Dennis; Brennan, John J; Coll, Blai; Correa-Rotter, R; de Zeeuw, Dick; et al, Various; Houser, Mark; Kohan, Donald; Lambers Heerspink, Hiddo; Makino, Hirofumi; Tang, Hui; The George Institute for Global HealthThe endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy, Journal of the American Society of Nephrology, vol.25, 5, 2014,pp 1083-1093
2011Is doubling of serum creatinine a valid clinical 'hard' endpoint in clinical nephrology trials?Perkovic, Vlado; de Zeeuw, Dick; Lambers Heerspink, Hiddo J; The George Institute for International HealthIs doubling of serum creatinine a valid clinical 'hard' endpoint in clinical nephrology trials?, Nephron Clinical Practice, vol.119, 3, 2011,pp c195-c199
2016Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markersPerkovic, Vlado; Andress, Dennis; Brennan, John J; Coll, Blai; Correa-Rotter, R; de Zeeuw, Dick; et al, Various; Hou, Fanfan; Kohan, Donald; Schievink, Bauke; Smink, Paul A; The George Institute for Global HealthPrediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers, European Journal of Preventive Cardiology, vol.23, 7, 2016,pp 758-768
2017Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trialFulcher, Greg; Neal, Bruce; Perkovic, Vlado; de Zeeuw, Dick; Deng, Hsiaowei; Desai, Mehul; Erondu, N; Mahaffey, Kenneth W; Matthews, David; Meininger, Gary; Shaw, Wayne; Vercruysse, Frank; Yee, Jacqueline; Northern Clinical School: Medicine; The George Institute for Global Health; The George Institute for Global HealthRationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial, Diabetes, Obesity and Metabolism, vol.19, 3, 2017,pp 387-393
2013Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)-A randomized placebo-controlled trialFulcher, Greg; Neal, Bruce; Perkovic, Vlado; de Zeeuw, Dick; Desai, Mehul; Jiang, Joel; Mahaffey, Kenneth; Matthews, David; Meininger, G; Shaw, Wayne; Stein, Peter; Vercruysse, Frank; Northern Clinical School: Medicine; The George Institute for Global Health; The George Institute for Global HealthRationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)-A randomized placebo-controlled trial, American Heart Journal, vol.166, 2, 2013,pp 217-223
2009Renal and cardio-protective effects of direct renin inhibition: a systematic literature reviewLambers Heerspink, Hiddo; Perkovic, Vlado; de Zeeuw, Dick; The George Institute for International Health; The George Institute for International HealthRenal and cardio-protective effects of direct renin inhibition: a systematic literature review, Journal of Hypertension, vol.27, 12,pp 2321-2331